GSK Files For Japan Approval Of LABA/LAMA Drug For COPD Treatment
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline has filed for the approval in Japan of its combination drug containing the long-acting muscarinic antagonist meclidinium and the long-acting β2-agonist vilanterol for the treatment of chronic obstructive pulmonary disease, the company said April 22.